Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells

Bortezomib (Velcade™) is a reversible proteasome inhibitor that is approved for the treatment of multiple myeloma (MM). Despite its demonstrated clinical success, some patients are deprived of treatment due to primary refractoriness or development of resistance during therapy. To investigate the rol...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Erika, Demo, Susan, Deu, Edgar, Keats, Jonathan, Arastu-Kapur, Shirin, Bergsagel, P. Leif, Bennett, Mark K., Kirk, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245226/
https://www.ncbi.nlm.nih.gov/pubmed/22216088
http://dx.doi.org/10.1371/journal.pone.0027996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245226/
https://www.ncbi.nlm.nih.gov/pubmed/22216088
http://dx.doi.org/10.1371/journal.pone.0027996

Ejemplares similares